Clinical effect analysis of cytarabine consolidation in the treatment of acute myeloid leukemia
阿糖胞苷巩固治疗初治急性髓系白血病临床效果分析

摘要

目的 分析在初治急性髓系白血病患者中运用阿糖胞苷巩固治疗的临床效果。方法 此文病例筛选我医院接收的初治急性髓系白血病患者60例，将纳入的所有病例运用电脑随机抽取方式划分为两组进行对照研究，组别主要分成观察组和对照组，每组中的患者人数分别有30例，两组患者均采用柔红霉素治疗，同时给予对照组患者中剂量阿糖胞苷巩固治疗，观察组则给予标准剂量阿糖胞苷巩固治疗，将两组最终取得的治疗效果进行对比。结果 治疗后两组各项指标结果对比显示，观察组患者获得的治疗总有效率与对照组相比明显提高，患者的免疫指标、胰岛素样生长因子及白血病抑制因子水平与对照组相比得到显著改善，患者用药不良反应发生率明显低于对照组（P＜0.05）。结论 对急性髓系白血病患者治疗中添加阿糖胞苷进行巩固治疗，可有效提升临床治疗效果，使患者的临床各项指标能够得到良好改善，且用药安全性也较高，因此能够提高患者疾病控制效果，降低疾病危害性。

Abstract

Objective: To analyze the clinical effect of cytarabine consolidation therapy in newly treated patients with acute myeloid leukemia.
Methods: In this paper, 60 cases of newly treated acute myeloid leukemia patients received by our hospital were screened, and all included cases were randomly selected into two groups for control study. The group was mainly divided into observation group and control group, with 30 patients in each group, and both groups were treated with daunorubicin. Meanwhile, the control group was given a medium dose of cytarabine consolidation treatment, while the observation group was given a standard dose of cytarabine consolidation treatment. Finally, the therapeutic effects of the two groups were compared.
Results: after treatment, according to the results of two groups of the indicators for the total effective rate of observation group patients increased significantly compared with control group, the patient's immune index, insulin-like growth factor and leukemia inhibitory factor level improved significantly compared with control group, the incidence of drug adverse reaction in patients with significantly lower than the control group (P < 0.05).
Conclusion  : Adding cytarabine in the treatment of acute myeloid leukemia patients for consolidation therapy can effectively improve the clinical treatment effect, so that the clinical indicators of patients can be well improved, and the safety of medication is high, so it can improve the disease control effect of patients, reduce the harm of the disease.